Please login to the form below

Seattle Genetics

This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.

Latest news

Seattle Genetics claims key US approval for Adcetris

Seattle Genetics claims key US approval for Adcetris. Becomes the first new treatment for advanced Hl in more than 40 years. ... Seattle Genetics has won FDA approval for Adcetris as a first-line treatment for advanced Hodgkin’s lymphoma, which it
Takeda bags EU approval for Adcetris in lymphoma

Originally developed by Seattle Genetics, Adcetris has been on the market for just over six years and has seen sales grow steadily to around $600m last year, driven by a stream ... There are more new indications on the way, and Takeda and Seattle
Seattle Genetics' Adcetris earns FDA priority review status

Seattle Genetics' Adcetris earns FDA priority review status. The win follows a breakthrough designation from the US regulator last year. ... Seattle Genetics’Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the
Astellas extends phase III programme for Rydapt rival gilteritinib

It also has a 10-year-plus collaboration with Seattle Genetics covering microtubule-disrupting antibody-drug conjugates.
Activists torpedo Immunomedics deal with Seattle Genetics

Activists torpedo Immunomedics deal with Seattle Genetics. venBio says deal will enrich CEO at shareholders' expense. ... Immunomedics $2bn deal licensing its triple-negative breast cancer (TNBC) candidate IMMU-132 to Seattle Genetics has been abandoned

More from news
Approximately 6 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
Deal Watch March 2017

In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
Deal Watch February 2017

Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
Pharma deals in June 2015

NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
Deal Watch table for September 2014

244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

Douglas Williams named president and CEO of Codiak

These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
VentiRx appoints James Kyle Bryan as chief medical officer

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Delivery Manager/ Head of Delivery – Executive Search: Neg

Senior Project Manager - Medical Writing: Great salary and bebefits

Senior Account Manager: Competitive salary commensurate with experience

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager: £40, 000 - £45, 000 benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Client Services Director - Med Comms: Great salary and bebefits

Business Unit Head, Medical Communications, London: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Editorial Director – Medical Education (MedComms): Neg

Subscribe to our email news alerts

PMHub

Add my company

VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....